Bergen, Norway,10 October 2024 - An Extraordinary general meeting of BerGenBio
ASA was virtually held today 10 October 2024 at 10.00 CEST.
All proposals were resolved as presented in the notice convening the
extraordinary general meeting distributed on 19 September 2024 as further set
out in the minutes from the extraordinary general meeting attached hereto and
available at https://www.bergenbio.com/investors/general-meetings/.
For further information, please contact:
Martin Olin
CEO, BerGenBio ASA
ir@bergenbio.com
Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.